Biblio Discovery — Demo Discovery Service

4 results for "Simran Chandra"

Showing 1–4 · 0.06 seconds · RSS

  1. Journal Article

    Case Report: Luspatercept for transfusion-dependent anemia of unknown etiology

    Simran Chandra; Vasu Bansal; Parth Sharma et al.

    Frontiers in Hematology, Vol. 4 · 2026 · English · DOAJ Scopus

    Anemia is a common clinical problem with diverse etiologies. Transfusion-dependent anemia (TDA), defined by the need for frequent red blood cell transfusions, can arise from various hematologic disorders. However, in rare instances, despite extensive diagnostic evaluation, the underlying cause may…

  2. Journal Article

    Ceftazidime–avibactam for the Treatment of Intra-abdominal Sepsis and Urosepsis: A Retrospective Hospital-based Study in India

    Prachee Sathe; Chitra Lele; Simran Chandra et al.

    International Journal of Advanced Medical and Health Research, Vol. 11 No. 2 · 2024 · English · DOAJ

    Background: In India, microbial susceptibility to antibiotics has been gradually decreasing, thus making treatment of multidrug-resistant bacterial infections challenging. We aimed to assess the effectiveness of ceftazidime–avibactam in patients with intra-abdominal sepsis or urosepsis. Methods…

  3. Journal Article

    Successful rechallenge of BRAF/MEK inhibitor with ruxolitinib in BRAF/MEK inhibitor-induced hemophagocytic lymphohistiocytosis like hyperinflammatory syndrome in BRAF V600E-mutated lung adenocarcinoma: a case report

    Simran Chandra; Sagar Hansraj; Aakriti Adhikari et al.

    Frontiers in Oncology, Vol. 16 · 2026 · English · DOAJ Scopus

    Dabrafenib and trametinib are highly efficacious therapies in patients with BRAF V600E-mutated lung adenocarcinoma (LUAD), but they are occasionally associated with the development of hemophagocytic lymphohistiocytosis (HLH). Here, we describe the first reported case of metastatic BRAF…

  4. Journal Article Full text

    Immune checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis in lung cancer: a case series

    Abdul Wali Khan; Simran Chandra; Himil Mahadevia et al.

    Exploration of Targeted Anti-tumor Therapy, Vol. 6 · 2025 · English · DOAJ Scopus

    Immune checkpoint inhibitors (ICIs) are established treatments for various malignancies, including lung, kidney, and colorectal cancers. However, their broad use has led to an increase in immune-related adverse events (irAEs), with thyroiditis, colitis, and pneumonitis being the most common…